Flagship VenturesHelicos Biosciences Corp • August 29th, 2012 • Pharmaceutical preparations • Massachusetts
Reference is made to the Risk Premium Payment Agreement, dated as of November 16, 2010 (the “Risk Premium Agreement”), by and among the lenders listed on the signature pages hereto (the “Lenders”) and Helicos BioSciences Corporation (the “Company”) and the Subordinated Secured Note Purchase Agreement, dated as of November 16, 2010, as amended to date (the “NPA”), by and among the Lenders and the Company. Capitalized terms used herein without definition shall have the respective meanings assigned to such terms in the Risk Premium Agreement.
